Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer - A Proof of Concept, Open Label Non-randomized Phase IIa Study. The AVETUXIRI Trial

Next Previous
Trial Profile

Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer - A Proof of Concept, Open Label Non-randomized Phase IIa Study. The AVETUXIRI Trial

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Cetuximab (Primary) ; Irinotecan (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms AVETUXIRI

Most Recent Events

  • 24 Oct 2023 Results (n=55) characterizing the immune response for biomarker discovery through associated translational research presented at the 48th European Society for Medical Oncology Congress
  • 24 Oct 2023 Results (n=57) assessing the efficacy and safety of Avelumab, cetuximab and irinotecan for the treatment of refractory microsatellite stable metastatic colorectal cancer, presented at the 48th European Society for Medical Oncology Congress.
  • 07 Jun 2022 According to interim results presented at the 58th Annual Meeting of the American Society of Clinical Oncology, this study met its preliminary primary efficacy endpoint for continuation.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top